Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7318656 | 0.92 | ALDH1A1 (0.51) | GAACYP2C9CYP2C19ALDH1A1KMT2A | |
| SCHEMBL10924999 | 0.87 | CYP2C19 (0.45) | GAACYP2C9CYP2C19ALDH1A1KMT2A | |
| SCHEMBL10922397 | 0.85 | CYP2C19 (0.44) | GAACYP2C9CYP2C19ALDH1A1KMT2A | |
| Bromide SCHEMBL7142006 | 0.84 | CYP2C19 (0.43) | GAACYP2C9CYP2C19ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL7291893 | 0.84 | CYP2C19 (0.43) | GAACYP2C9CYP2C19ALDH1A1KMT2A | |
| SCHEMBL3618682 | 0.79 | CYP2C9 (0.39) | GAACYP2C9CYP2C19ALDH1A1KMT2A | |
| SCHEMBL8804527 | 0.78 | ALDH1A1 (0.52) | CYP2C9CYP2C19ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7318796 | 0.77 | ALDH1A1 (0.51) | CYP2C9CYP2C19ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL16561279 | 0.76 | ALDH1A1 (0.50) | GAACYP2C9CYP2C19ALDH1A1KMT2A | |
| Bromide SCHEMBL9747692 | 0.76 | ALDH1A1 (0.50) | CYP2C9CYP2C19ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009101917-A1 | BICYCLOAMINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | WO | disclosed |
| EP-0196132-A2 | 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-01 | — | — | EP | disclosed |
| EP-0070053-B1 | NOVEL BICYCLIC PYRIMIDIN-5-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-04-16 | — | — | EP | disclosed |
| US-4581171-A | ANTISEROTONINE AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1986-04-08 | — | — | US | disclosed |
| US-4548938-A | PSYCHOTROPIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-10-22 | — | — | US | disclosed |
| US-4533665-A | SEROTONIN ANTAGONIST | JANSSEN PHARMACEUTICA (BE) | 1985-08-06 | — | — | US | disclosed |
| US-4529727-A | Pyrimido[2,1-b][1,3]-thiazines | JANSSEN PHARMACEUTICAL, N.V. (BE) | 1985-07-16 | — | — | US | disclosed |
| EP-0144101-A2 | Bicyclic heterocyclyl containing N-(bicyclic heterocyclyl)-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-12 | — | — | EP | disclosed |
| US-4485107-A | SEDATIVES, MUSCLE RELAXANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-11-27 | — | — | US | disclosed |
| EP-0110435-A1 | Novel ((bis(aryl)methylene)-1-piperidinyl)alkyl-pyrimidinones | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-06-13 | — | — | EP | disclosed |
| US-4443451-A | PSYCHOTROPIC, ANTIHISTAMINES, ANTISEROTONINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | GAA 4207/4885CYP2C9 357/4885CYP2C19 359/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | GAA 4207/4885CYP2C9 357/4885CYP2C19 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.